NCT01797185

Safety Study of SPARC1104

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 375 (actual)
• Sponsor: Sun Pharma Advanced Research Company Limited · Industry
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

Open-label, safety study of SPARC1104 in subjects with spasticity due to multiple sclerosis

Detailed description

Safety study of SPARC1104

Conditions

• Spasticity

Interventions

Type	Name	Description
DRUG	SPARC1104 modified dose regimen I	Subjects who exited study CLR\_09\_21
DRUG	SPARC1104 modified dose regimen II	Subjects who received prior treatment regimen I
DRUG	SPARC1104 modified dose regimen III	Subjects who received no prior treatment regimen

Timeline

• Start date: 2013-04-09
• Primary completion: 2017-07-01
• Completion: 2017-10-01
• First posted: 2013-02-22
• Last updated: 2019-05-03
• Results posted: 2019-03-12

Locations

51 sites across 1 country: United States